Are the benefits of value-based insurance design conclusive?

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Questions about the clinical significance of improvements to medication adherence resulting from value-based insurance design (VBID) policies persist in the literature. Given the lack of conclusive evidence about effectiveness, in addition to concerns about the cost of implementing VBID programs, it is perhaps not surprising that VBID is not more widely used by managed care plans. Although VBID holds promise for improving chronic medication use, additional evidence is needed if VBID is to become universally adopted.

Original languageEnglish (US)
Pages (from-to)736-738
Number of pages3
JournalJournal of Managed Care and Specialty Pharmacy
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2019

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Are the benefits of value-based insurance design conclusive?'. Together they form a unique fingerprint.

Cite this